翰森制药1类新药达麦利替尼申报上市

医药时间02-27

2月27日，中国国家药监局药品审评中心（CDE）官网公示显示，翰森制药1类新药甲磺酸达麦利替尼片上市申请获得受理，具体适应症尚未披露。公开资料显示，这是翰森制药在研的c-MET TKI（研发代号：HS-10241）。该产品联合甲磺酸阿美替尼片对比含铂双药化疗用于经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗失败伴间质-上皮转化因子（MET）扩增的晚期非小细胞肺癌（NSCLC）的关键3期...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2614832360?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-27 15:23","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2614832360","market":"hk","top_or_hot":-1,"title":"翰森制药1类新药达麦利替尼申报上市","media":"医药时间","content":"<div>\n<p>2月27日，中国国家药监局药品审评中心（CDE）官网公示显示，翰森制药1类新药甲磺酸达麦利替尼片上市申请获得受理，具体适应症尚未披露。公开资料显示，这是翰森制药在研的c-MET TKI（研发代号：HS-10241）。该产品联合甲磺酸阿美替尼片对比含铂双药化疗用于经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗失败伴间质-上皮转化因子（MET）扩增的晚期非小细胞肺癌（NSCLC）的关键3期...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227154022a4ced162&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰森制药1类新药达麦利替尼申报上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰森制药1类新药达麦利替尼申报上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-27 15:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227154022a4ced162&s=b><strong>医药时间</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2月27日，中国国家药监局药品审评中心（CDE）官网公示显示，翰森制药1类新药甲磺酸达麦利替尼片上市申请获得受理，具体适应症尚未披露。公开资料显示，这是翰森制药在研的c-MET TKI（研发代号：HS-10241）。该产品联合甲磺酸阿美替尼片对比含铂双药化疗用于经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗失败伴间质-上皮转化因子（MET）扩增的晚期非小细胞肺癌（NSCLC）的关键3期...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227154022a4ced162&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227154022a4ced162&s=b","article_id":"2614832360","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227154022a4ced162&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614832360","pubTimestamp":1772177017,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2月27日，中国国家药监局药品审评中心官网公示显示，翰森制药1类新药甲磺酸达麦利替尼片上市申请获得受理，具体适应症尚未披露。翰森制药此前在美国临床肿瘤学会年会上公布了HS-10241联合阿美替尼在既往经过治疗的EGFR突变晚期NSCLC患者中的1b期研究结果。在13例经中心实验室确认的EGFR敏感突变且MET扩增，缓解率61.5%，5例确认的PR，4例SD。药代动力学特征方面，HS-10241联合阿美替尼的潜在药物相互作用风险较低。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","03692":"翰森制药","BK1589":"北水核心资产"},"translate_title":"Hansoh Pharmaceutical's Class 1 new drug Damalitinib applies for marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1.5},"content_text":"2月27日，中国国家药监局药品审评中心（CDE）官网公示显示，翰森制药1类新药甲磺酸达麦利替尼片上市申请获得受理，具体适应症尚未披露。公开资料显示，这是翰森制药在研的c-MET TKI（研发代号：HS-10241）。该产品联合甲磺酸阿美替尼片对比含铂双药化疗用于经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗失败伴间质-上皮转化因子（MET）扩增的晚期非小细胞肺癌（NSCLC）的关键3期临床研究此前已经完成。翰森制药此前在美国临床肿瘤学会（ASCO）年会上公布了HS-10241联合阿美替尼在既往经过治疗的EGFR突变晚期NSCLC患者中的1b期研究结果。研究表明，HS-10241联合阿美替尼治疗具有良好的耐受性和安全性，并在既往EGFR TKI进展后EGFR突变且MET扩增（无论MET GCN≥10还是MET GCN≥5但<10）的晚期NSCLC中均显示出令人鼓舞的有效性。具体而言，截至2022年12月16日，共纳入了45例受试者，包括递增期10例和扩展期35例。安全耐受性方面，递增期阶段仅在HS-10241 300mg BID联合阿美替尼110mg QD的6例患者中，报告了1例剂量限制性毒性，未达到MTD。在所有的45例患者中，有41例（91.1%）发生了TEAE。有效性方面，共有22名EGFR突变（无论MET基因状态如何）的患者疗效可评估，其中12名患者获得疾病缓解（PR），缓解率54.5%，其中8例确认的PR，7例患者疾病稳定（SD）。在13例经中心实验室确认的EGFR敏感突变且MET扩增，缓解率61.5%，5例确认的PR，4例SD。此外，在9例接受过1/2代和3代EGFR TKI均进展的患者中，6例出现PR，缓解率66.7%，3例确认的PR，2例SD。药代动力学特征方面，HS-10241联合阿美替尼的潜在药物相互作用（DDI）风险较低。来源：医药观澜","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614832360","isCrawlerRequest":true}